Background: Large-cell carcinoma (LCC) and large-cell neuroendocrine carcinoma (LCNEC) are kinds of rare lung tumors classified as distinct forms of non-small-cell lung cancer (NSCLC). They both differ in cellular morphology, neuroendocrine marker expression, and clinical outcomes. Thus, LCC and LCNEC exhibit different clinicopathological characteristics and survival outcomes. This study seeks to assess how clinicopathological and immunohistochemical features influence the need for adjuvant chemotherapy in individuals with early-stage, surgically resected LCC or LCNEC. Methods: This multicenter retrospective analysis included 79 patients who underwent surgical resection for large-cell carcinoma (LCC) or large-cell neuroendocrine carcinoma (LCNEC) between January 2008 and March 2025. We evaluated prognostic factors that influence survival in patients with LCC and LCNEC and assessed the effect of adjuvant chemotherapy on survival outcomes. Results: This study included 79 patients—39 diagnosed with LCC and 40 diagnosed with LCNEC. All patients were in stages I–III and received curative surgery. The median age was 61 years for LCC patients and 58.5 years for LCNEC patients. The median overall survival (mOS) was 80.1 months for patients with LCC and 34.2 months for those with LCNEC. Multivariate Cox regression analysis revealed that age (HR: 0.279), stage (HR: 0.198), and chromogranin A expression (HR: 0.088) were independent prognostic factors for overall survival in LCC patients. In LCNEC patients, stage (HR: 0.20), synaptophysin expression (HR: 0.30), type of surgery (HR: 0.31), and adjuvant chemotherapy (HR: 0.264) were identified as factors influencing overall survival. Adjuvant chemotherapy improved overall survival in LCNEC patients (67.0 vs. 17.8 months). Conclusions: Patients with LCNEC generally have poorer prognoses than those with LCC, exhibiting reduced overall survival periods. Disease stage is the most significant factor influencing overall survival for both groups. Notably, in LCNEC patients, adjuvant chemotherapy was found to independently improve survival outcomes regardless of stage.
Schwannomas are benign nerve sheath tumors most commonly located in the posterior mediastinum. However, atypically located thoracic schwannomas are rare and may pose challenges in diagnosis and surgical management. In this retrospective case series, 14 patients who underwent surgical treatment for atypically located thoracic schwannomas between 2011 and 2025 were evaluated. Demographic, clinical, radiological, surgical, and histopathological data were analyzed. The associations between tumor location and clinical or surgical variables were assessed using Fisher’s exact test and the Chi-square test. The mean age of the patients was 51.4 years (range: 24–77), with a predominance of male cases. Tumor locations were classified as supraclavicular (n = 4), anterior/middle mediastinum (n = 4), infraclavicular (n = 2), chest wall (n = 3), and lung parenchyma (n = 1). Pain was the most common presenting symptom. All patients underwent curative (R0) surgical resection. Surgical approaches included VATS (n = 4), RATS (n = 1), thoracotomy (n = 3), and modified open techniques (n = 6). No statistically significant association was found between tumor location and complication rates, surgical method, or length of hospital stay. No recurrences were observed during a mean follow-up period of 48 months. Although rare, atypically located thoracic schwannomas should be considered in the differential diagnosis of intrathoracic masses. With accurate preoperative imaging and proper surgical planning, these lesions can be safely and completely resected, resulting in favorable clinical outcomes. Graphical abstract
Background: Adenocarcinoma (AC) is the leading histopathological type of lung cancer (LC), curative surgery being the cornerstone for the best survival results. However, even in the patients who had curative surgery, the survival outcomes differ. Spread through air spaces (STAS), recognized as a histopathological feature in the 2015 World Health Organization (WHO) Classification, causes poor survival outcomes in lung AC. This study aimed to evaluate the prognostic impact of STAS on recurrence-free survival (RFS) and overall survival (OS) in surgically resected T1-2N0 lung AC, with particular attention to its interaction with tumor size. Methods: This single center retrospective study evaluates the effect of STAS on RFS and OS in 296 surgically resected T1-2N0 lung AC patients. For further analysis, patients were divided into four subgroups combining their STAS status and tumor size. Results: STAS presence rate was 37.5%, which was associated with aggressive tumor characteristics, such as non-lepidic predominant subtypes, higher pathological T stage (pT), visceral pleura invasion (VPI), and lymphovascular invasion (LVI). OS and RFS were significantly worse in the STAS-Present (STAS-P) group ( p = 0.030). Subgroup analysis revealed that STAS-P tumors > 2 cm had the worst outcomes, as expected. Notably, on univariate analysis STAS presence appeared most prognostically decisive in tumors ≤ 2 cm, in which there was no significant difference in survival between STAS-P tumors ≤ 2 cm and STAS-Absent (STAS-A) tumors > 2 cm. Conclusions: STAS was a significant prognostic factor on univariate analysis but did not retain independent significance after multivariable adjustment. In an exploratory subgroup analysis, STAS-P tumors ≤ 2 cm carried survival outcomes comparable to STAS-A tumors > 2 cm, suggesting STAS may attenuate the prognostic advantage of smaller tumor size. This hypothesis-generating finding warrants prospective validation before informing surgical management.